Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

More documents

Recommendations

Info

Key drivers for long term development in place Develop the short term drivers while not ‘leaving ‘ the others Inherent development risk Low High ILLUSTRATIVE Oncology Inflammation existing Earlier Phases Maturity of portfolio Virology CNS Metabolic 30
CD20 targeting: new treatment strategy for MS Very promising signals from Phase II with rituximab • Total cumulative mean number of gadolinium lesions was reduced by 91 %, p
Page 1 and 2: Clinical Development at Roche: Driv
Page 3 and 4: Our new R&D model: Paradigm changes
Page 5 and 6: Biomarkers A central element throug
Page 7 and 8: Our new R&D model: Paradigm changes
Page 9 and 10: Enhance innovation …by maintainin
Page 11 and 12: Roche Pharma pipeline overview Focu
Page 13 and 14: Major Roche-managed oncology submis
Page 15 and 16: Avastin and cetuximab in combinatio
Page 17 and 18: Avastin and cetuximab in combinatio
Page 19 and 20: Attacking the HER2 pathway from mul
Page 21 and 22: Implementing biomarker strategy for
Page 23 and 24: Key drivers for long term developme
Page 25 and 26: Actemra: The first IL-6 receptor in
Page 27 and 28: CETP Inhibitor R1658 is a unique CE
Page 29: Taspoglutide: investigational once-
Page 33 and 34: Roche R&D opportunities in summary
Page 35 and 36: Avastin’s position as standard of

Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

Create successful ePaper yourself

Delete template?

Save as template?